Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

Erytech Pharma SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

28 Mar 2015 Reuters Investment Profile 12 $20.00

Wright Investors Service Comprehensive Report for Erytech Pharma SA

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

27 Feb 2015 Wright Reports 55 $75.00

Erytech Pharma SA (ERYP) - Financial Analysis Review

Erytech Pharma SA (ERYP) - Financial Analysis Review Summary Erytech Pharma SA (Erytech Pharma) is a bio-pharmaceutical...

12 Feb 2015 GlobalData 38 $125.00

ERYTECH PHARMA - DEUTSCHES EIGENKAPITALFORUM

Graspa has successfully completed a Phase III trial in acute lymphoblastic leukaemia (ALL), which should pave the way for fir...

28 Jan 2015 Edison Investment Research 2 $10.00

Company Snapshot - Erytech Pharma

A director at Erytech Pharma sold 34,000 shares at 29.600EUR and the significance rating of the trade was 71/100. Is that in...

26 Jan 2015 Directors Deals Ltd. 1 $12.00

ERYTECH PHARMA - MORE DETAILED GRASPA DATA REINFORCE ITS POTENTIAL

Additional details on Erytech’s Graspa Phase III acute lymphoblastic leukaemia (ALL) trial have been disclosed in conjunction...

06 Jan 2015 Edison Investment Research 7 $10.00

Erytech Pharma SA (ERYP) - Financial Analysis Review

Erytech Pharma SA (ERYP) - Financial Analysis Review Summary Erytech Pharma SA (Erytech Pharma) is a bio-pharmaceutical...

10 Dec 2014 GlobalData 40 $125.00

Company Snapshot - Erytech Pharma

A director at Erytech Pharma sold 1,370 shares at 28.000EUR and the significance rating of the trade was 53/100. Is that inf...

08 Dec 2014 Directors Deals Ltd. 1 $12.00

ERYTECH PHARMA - GOING GREAT WITH GRASPA

Erytech’s positive Graspa Phase III ALL data pave the way for European filing in H115, and the lack of allergic reactions in ...

14 Oct 2014 Edison Investment Research 12 $10.00

ERYTECH PHARMA - AML DE-RISKING; ALL UPCOMING

Erytech is approaching the key Graspa Phase III ALL (acute lymphoblastic leukaemia) data, which is anticipated in early Q414....

08 Sep 2014 Edison Investment Research 5 $10.00